| P/E (FY) | — | Sales (TTM) | — |
| Earnings (TTM) | -$242.0M | ROE | −118.70% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Sana Biotechnology is a biotechnology company focused on using engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for areas including type 1 diabetes, B cell-mediated autoimmune diseases, and oncology. Its pipeline includes UP421, a HIP-modified allogeneic islet cell product in Phase 1 for type 1 diabetes; SC451, a stem cell-derived islet therapy; and SG293 and SG299, CD8-targeted fusosomes. It has a license agreement with Beam Therapeutics.
| Market Cap | $915.6M | Trading Days | 1359 |
| 52W High | 6.55 |
| 52W Low | 2.61 |
| % Off High | −49.77% |
| YTD | −19.16% | 1Y | −32.58% |
| 3Y | −43.47% | 5Y | −80.54% |
| Since incept. (ann.) | −36.25% |
| Ann. Volatility (1Y) | 91.82% | Ann. Volatility (3Y) | 134.32% |
| Sharpe (1Y) | 0.02 | Sharpe (3Y) | 0.37 |
| Max Drawdown (1Y) | −54.73% | Max Drawdown (3Y) | −88.11% |
| Beta (3Y, vs SPY) | 3.83 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ODTX | Odyssey Therapeutics, Inc. | $914.0M | — |
| SLDB | Solid Biosciences Inc. | $784.6M | — |
| CGEM | Cullinan Therapeutics, Inc. | $1.07B | — |
| VOR | Vor Biopharma Inc. | $1.08B | — |
| MGTX | MeiraGTx Holdings plc | $1.09B | — |
| AURA | Aura Biosciences, Inc. | $728.9M | — |
| INBX | Inhibrx Biosciences, Inc. | $1.17B | — |
| CADL | Candel Therapeutics, Inc. | $709.3M | — |
| NVAX | NOVAVAX INC | $1.21B | 2.9 |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.36B | — |
| ALLO | Allogene Therapeutics, Inc. | $573.0M |
| — |
| TECX | Tectonic Therapeutic, Inc. | $562.3M | — |
